sign-web

Daiichi Sankyo rocked by further job losses

pharmafile | December 9, 2015 | Appointment | Manufacturing and Production Daiichi, Daiichi Sankyo 

The Japanese pharma firm Daiichi Sankyo is to close an antibody-producing subsidiary in Germany, as the company continues to cut jobs globally.

Daiichi is already shedding up to 1,200 jobs – or about half its workforce – in the US, and announced plans in March to lay off 16% of its workforce in the States in a series of redundancies at its base in Parsippany, New Jersey.

About 40 employees at U3 Pharma GmbH in Martinsried, Germany, will be affected, the company says in a statement.

“Daiichi Sankyo intends to strengthen its global research and development capabilities by increasing efficiency and streamlining processes. Based on this objective, the global R&D capacities have been reviewed and the Company has decided to concentrate core research functions of Daiichi Sankyo Group in future.

“U3, with about 40 employees and which is engaged in research and development work on antibody targeting for cancer treatments, will transfer its current research and development tasks to the Biologics Function in Tokyo.

Daiichi Sankyo says it will provide a more detailed update on the impact of this announcement on its FY2015 business results at a later date.

Related Content

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …

louis-reed-pwckf7l4-no-unsplash_5

EMA validates two applications for datopotamab deruxtecan for cancer treatments

AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …

Daiichi Sankyo shares results for Ezharmia as lymphoma treatment

Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), …

Latest content